Navigation Links
Mass. General-based research center will investigate why immune system fails to control hepatitis C
Date:7/22/2009

A research consortium based at Massachusetts General Hospital (MGH) has been awarded $15 million from the National Institute of Allergy and Infectious Diseases to investigate how the hepatitis C virus (HCV) resists suppression and clearance by the immune system. The five-year grant will support a Cooperative Center for Translational Research in Human Immunology, which also will focus on how some individuals successfully recover from HCV while the infection becomes chronic in most of those infected, with a special emphasis on immunological events in the liver as the site of HCV replication.

"Hepatitis C is a major global health problem for which existing therapies are inadequate," says Raymond Chung, MD, director of Hepatology in the MGH Gastrointestinal Unit and co-director of the research center. "Improving our understanding of how and why the virus consistently evades immune system control should lead us to better ways of treating hepatitis C and possibly other chronic viral infections." Chung will lead a project to better define the role of the liver cells called hepatocytes in the innate and adaptive immune response to HCV infection.

Center co-director Paul Klenerman, PhD, of Oxford University will examine properties of the T cells that migrate to the liver in response to HCV infection. Additional principal investigators and project goals are:

  • Georg Lauer, MD, PhD, MGH Gastrointestinal Unit, and John Wherry, PhD, Wistar Institute investigate the functional capacity of CD4 and CD8 T cells within the liver in chronic HCV infection;
  • Todd Allen, PhD, Ragon Institute of MGH, MIT and Harvard, and Matthew Henn, PhD, Broad Institute of MIT and Harvard examine how selection pressure applied by T cells affects HCV evolution;
  • Gordon Freeman, PhD, Dana-Farber Cancer Institute develop a panel of reagents designed to modulate signaling in key immune cells;
  • Joseph Misdraji, MD, MGH Pathology create a library of liver cells and tissue from HCV-infected and uninfected patients to use in study experiments;
  • Nicholas Haining, MB, ChB, Dana-Farber develop high-throughput technology platforms to examine and modulate signals inhibiting the immune response.

Almost 170 million people worldwide are infected with HCV, 50 to 80 percent of whom will develop chronic hepatitis, which can lead to cirrhosis, liver cancer or liver failure. Identifying the factors that allow HCV to survive in spite of the immune response against the virus may also improve understanding of immune system failure in other chronic infections, including HIV, Epstein-Barr virus, and tuberculosis.


'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Health Affairs Report On Mass. Mandatory Insurance Law Confirms: Strong Public Option Must Be Included in National Health Reform
2. Yankee Equity Solution ("YES") Launches $50 Million Fund for Mass.-Based Medtech Companies
3. Mass. General Hospital receives Gates Foundation grant to expand HIV controllers study
4. AIDS Action Asks Mass. Public Health Council to Forge a State AIDS Plan to Help Stop HIV/AIDS Here
5. Double-Digit Rate Increases Expected Under Mass. Mandatory Health Law; 5% Cap on Rate Hikes Proposed
6. Mass. Judge Denies Request by Breastfeeding Mother for More Break Time on Medical Licensing Exam
7. Cryo-Cell Announces Celle(SM) Research and Development Collaboration for Chronic Wound Healing Management
8. Zucker Hillside Researchers to Receive Large Federal Grant to Test for the Early Treatment of Schizophrenia
9. Major NIMH research project to test approaches to altering the course of schizophrenia
10. Clinical Research Safety and Ethical Standards in Developing World Up to U.S. Levels, Report Says
11. Amgen Scholars Discover Their Potential During Summer Science Research Program and National Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... ... survivor Sandra Lee as keynote speaker for the 34th Annual Miami Breast Cancer ... making the announcement, PER® president, Phil Talamo, said, “We are delighted to have ...
(Date:1/17/2017)... ... January 17, 2017 , ... Twelve (12) years ... Athletic Training Education program forged a relationship built upon the foundation of sports ... is consists of both student members and certified members of the Athletic Trainers’ ...
(Date:1/16/2017)... ... January 16, 2017 , ... Etymotic Research, makers of high-fidelity ... electronic earplugs at the NSSF SHOT Show on January 17-20, 2017 at the ... is the shooting, hunting and outdoor trade show and conference for the firearms, ...
(Date:1/16/2017)... ... 2017 , ... Permobil has just completed the acquisition of ... systems has a well-earned reputation for premium quality, with a focus on fit ... in the custom seating business, which enjoys strong demand, and it complements Permobil’s ...
(Date:1/16/2017)... ... January 16, 2017 , ... Board-certified oculoplastic ... Journal , the official journal of The American Society for Aesthetic Plastic Surgery, ... The procedure is designed to correct drooping, retracted lower eyelids, which usually result ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... YORK , Jan. 17, 2017 Immune ... stage biopharmaceutical company, announced today that it will hold ... Symposium on Acute Leukemias (ISAL) XVI in ... is entitled:  "Reinforcing the Efficacy of Immunotherapy for the ... take place on Monday February 20 th , 2017 from ...
(Date:1/17/2017)... LONDON , January 17, 2017 ... poised to potentially earn millions in revenue with the ... prevent massive numbers of strokes with a simple test ... Biotech Companies with latest developments in the markets today ... PLC (NYSE: AZN ), Cancer Genetics, Inc. ...
(Date:1/17/2017)... 2017  Maureen L. Mulvihill, President and CEO ... 6 senior sales leaders to support the nationwide ... leaders were formerly part of the top producers ... recognized for their performance, they have a proven ... relationships with key customer constituencies. "I have ...
Breaking Medicine Technology: